AGRX stock is a pharmaceutical company that focuses on the development of drugs for cancer and other diseases. The stock has seen tremendous growth over the past few years, and it has been ranked by Forbes magazine as a Top 10 stock to own. If you’re thinking about buying a share of AGRX, you’ll want to read up on the company’s ranking and recent earnings report, so that you can make an informed decision about the future of the company.
If you’re a big fan of women’s health and want to invest in a new startup, you’ll definitely want to consider Agile Therapeutics (NASDAQ:AGRX). The company is developing prescription contraceptives for women and is headquartered in Princeton, New Jersey.
Its first approved product is Twirla. This is a once-weekly prescription combination hormonal contraceptive patch.
There are a number of product candidates in the pipeline. For instance, the aforementioned Twirla, and a rumored upcoming contraceptive called AG890, which is a low-dose non-daily version of the gizmo.
Agile has been aggressively raising capital since its IPO. A recently announced capital raise of $5 million will enable the company to produce two more quarters of funding. Moreover, it’s likely that more capital raises will happen over the next year.
In addition, the company has some big ideas. One is a connected TV ad that targets women 18 to 24. Another is a co-promotion program with group purchasing organization Afaxys.
The company has also incorporated Corium, a proprietary transdermal drug delivery system. As part of this, they are planning a commercial manufacturing process test. They are also planning on building a sales team of 50 to 90 reps.
The biggest drawback to this company is the lack of a solid balance sheet. However, the company does have a loan facility with Perceptive Advisors. This should help them get by. Plus, they just launched their first connected TV ad.
Finally, the company has a few other product ideas in the pipeline. Their most promising one is a low-dose non-daily, once-weekly prescription contraceptive patch known as Twirla. With this in hand, they are likely to be able to compete with some of the biggest names in the contraceptive space. While there is no guarantee that this will be successful, it’s still a worthy contender.
Although this company’s stock may be at the bottom of the pack, you can bet that the company will have an interesting year ahead of it. And the best time to buy is now. Make sure to keep an eye out for the company’s big announcements.
Twirla is a low-dose transdermal hormonal contraceptive patch developed by Agile Therapeutics, Inc. Using Skinfusion technology, it allows drug delivery through the skin and optimizes patient comfort. Unlike existing patches, Twirla offers a lower dose of estrogen. In addition, it is a less invasive option than rings. It delivers a once-weekly application for three weeks, followed by a week without a patch.
The FDA recently approved Twirla for use in women of reproductive potential. This means that it will be available for purchase and prescription in the U.S., and Agile is now preparing to launch the product into the market. Since a large percentage of the market for contraceptives is already dominated by vaginal rings, Twirla could help drive revenue-generating growth in the women’s health space.
Twirla’s low-dose, once-weekly application provides a lower dose of estrogen than other patches, allowing for fewer negative side effects. While the product is currently approved for women aged 18 to 24 years, it could expand its reach to older age groups.
Twirla is expected to be available for reimbursement in key states, such as California, Florida, New York, and Illinois, as well as Medicaid, which accounts for about one-third of the patch market. With a lower cost base, the company expects the product to be an acceleration to the revenue-generating women’s health space.
The company’s marketing strategy involves leveraging its co-promotion partnership with Afaxys. By the end of the third quarter, the company had penetrated Planned Parenthood and begun to convert a significant number of large account holders. During the fourth quarter, the company also expects to see further growth in the non-retail channel.
In the next few months, Agile will begin to hire a sales team to support the rollout of Twirla in the U.S., with the goal of building a sales force of about 50-90 reps. Depending on how Twirla’s formulary acceptance is received, Agile will be able to further ramp up the size of the sales team.
Twirla is currently available to women of reproductive potential who are eligible for Medi-Cal, which is the largest Medicaid program in the U.S. The company is working with Afaxys to promote the product to college student health centers and other healthcare organizations.
AGRX’s most recent earnings report
Agile Therapeutics (NASDAQ:AGRX) last reported earnings on November 7, 2022 after the market close. The company reported Non-GAAP income from continuing operations of $0.03 per share, compared to the consensus EPS estimate of $0.02. Since then, AGRX stock has slid -8.9%, but the price remains near the higher end of the range. During the same day, the company held an investor conference call at 4:30 PM Eastern. During the call, CEO Matt Riley talked about the company’s first quarter 2022 financial results. He also indicated that they expect the shares to rise in the first half of 2023.
Investors can use the upcoming earnings table to determine when the next earnings release is scheduled. This table will help you to see when AGRX stocks are expected to report earnings. You can then make an educated decision on whether to purchase a share of AGRX based on this information. It is important to read the earnings report guide, which will provide you with detailed information on the company.
Investors can also use the projected earnings date, which is the date the company predicts the next earnings release will occur. The projection is based on the algorithm and historical reporting dates. Once the company announces a date, the projected date will change.